New hope for tough lung cancers: Triple-Drug combo enters final testing

NCT ID NCT04655976

Summary

This study is for people with advanced non-small cell lung cancer that has worsened despite standard immunotherapy and chemotherapy. It compares three treatment approaches to see which helps patients live longer: standard chemotherapy alone, chemotherapy plus one immunotherapy drug, or chemotherapy plus two immunotherapy drugs. The main goal is to determine if the new drug combinations improve survival for this hard-to-treat cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER (NON-SMALL CELL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • GSK Investigational Site

    Fountain Valley, California, 92708, United States

  • GSK Investigational Site

    Walnut Creek, California, 94596, United States

  • GSK Investigational Site

    Norwich, Connecticut, 06360, United States

  • GSK Investigational Site

    Washington D.C., District of Columbia, 20422, United States

  • GSK Investigational Site

    Honolulu, Hawaii, 96819, United States

  • GSK Investigational Site

    Iowa City, Iowa, 52242, United States

  • GSK Investigational Site

    Edgewood, Kentucky, 41017, United States

  • GSK Investigational Site

    Las Vegas, Nevada, 89144, United States

  • GSK Investigational Site

    Mineola, New York, 11501, United States

  • GSK Investigational Site

    New York, New York, 10016, United States

  • GSK Investigational Site

    White Plains, New York, 10601, United States

  • GSK Investigational Site

    Pittsburgh, Pennsylvania, 15224, United States

  • GSK Investigational Site

    Pittsburgh, Pennsylvania, 15232, United States

  • GSK Investigational Site

    Sioux Falls, South Dakota, 57105, United States

  • GSK Investigational Site

    Houston, Texas, 77030, United States

  • GSK Investigational Site

    Fredericksburg, Virginia, 22408, United States

  • GSK Investigational Site

    Tacoma, Washington, 98405, United States

  • GSK Investigational Site

    Buenos Aires, C1426ABP, Argentina

  • GSK Investigational Site

    Cipoletti Rio Negro, R8324CVE, Argentina

  • GSK Investigational Site

    Ciudad Autonoma de Buenos Aire, 1425, Argentina

  • GSK Investigational Site

    Florida, 1602, Argentina

  • GSK Investigational Site

    La Rioja, F5300COE, Argentina

  • GSK Investigational Site

    Pergamino, B2700CPM, Argentina

  • GSK Investigational Site

    Rosario, S2000DBS, Argentina

  • GSK Investigational Site

    Viedma, R8500ACE, Argentina

  • GSK Investigational Site

    South Brisbane, Queensland, 4101, Australia

  • GSK Investigational Site

    Ashford, South Australia, 5037, Australia

  • GSK Investigational Site

    Hobart, Tasmania, 7000, Australia

  • GSK Investigational Site

    Ballarat, Victoria, 3350, Australia

  • GSK Investigational Site

    Melbourne, Victoria, 3004, Australia

  • GSK Investigational Site

    Mount Waverley, Victoria, 3350, Australia

  • GSK Investigational Site

    Aalst, 9300, Belgium

  • GSK Investigational Site

    Hasselt, 3500, Belgium

  • GSK Investigational Site

    Kortrijk, 8500, Belgium

  • GSK Investigational Site

    Blumenau, 89010340, Brazil

  • GSK Investigational Site

    Fortaleza, 60336-232, Brazil

  • GSK Investigational Site

    Porto Alegre, 90610000, Brazil

  • GSK Investigational Site

    Rio de Janeiro, 22061080, Brazil

  • GSK Investigational Site

    Rio de Janeiro, 22250-905, Brazil

  • GSK Investigational Site

    Salvador, 40170-110, Brazil

  • GSK Investigational Site

    São Paulo, 04014-002, Brazil

  • GSK Investigational Site

    Greater Sudbury, Ontario, P3E 5J1, Canada

  • GSK Investigational Site

    Kingston, Ontario, K7L 2V7, Canada

  • GSK Investigational Site

    Oshawa, Ontario, L1G 2B9, Canada

  • GSK Investigational Site

    Greenfield Park, Quebec, J4V 2H1, Canada

  • GSK Investigational Site

    Montreal, Quebec, H3T 1E2, Canada

  • GSK Investigational Site

    Helsinki, 00180, Finland

  • GSK Investigational Site

    Kuopio, 70210, Finland

  • GSK Investigational Site

    Créteil, 94010, France

  • GSK Investigational Site

    Grenoble, 38043, France

  • GSK Investigational Site

    Marseille, 13009, France

  • GSK Investigational Site

    Nice, 06189, France

  • GSK Investigational Site

    Quimper, 29107, France

  • GSK Investigational Site

    Rennes, 35033, France

  • GSK Investigational Site

    Tours, 37044, France

  • GSK Investigational Site

    Augsburg, 86156, Germany

  • GSK Investigational Site

    Bad Berka, 99437, Germany

  • GSK Investigational Site

    Berlin, 12200, Germany

  • GSK Investigational Site

    Bonn, 53113, Germany

  • GSK Investigational Site

    Cologne, 51109, Germany

  • GSK Investigational Site

    Dresden, 01307, Germany

  • GSK Investigational Site

    Essen, 45147, Germany

  • GSK Investigational Site

    Frankfurt, 60488, Germany

  • GSK Investigational Site

    Frankfurt, 60590, Germany

  • GSK Investigational Site

    Halle, 06120, Germany

  • GSK Investigational Site

    Heidelberg, 69126, Germany

  • GSK Investigational Site

    Karlsruhe, 76137, Germany

  • GSK Investigational Site

    München, 80336, Germany

  • GSK Investigational Site

    München, 81925, Germany

  • GSK Investigational Site

    Oldenburg, 26121, Germany

  • GSK Investigational Site

    Athens, 115 27, Greece

  • GSK Investigational Site

    Athens, 11526, Greece

  • GSK Investigational Site

    Athens, 11528, Greece

  • GSK Investigational Site

    Athens, 12462, Greece

  • GSK Investigational Site

    Larissa, 41100, Greece

  • GSK Investigational Site

    Pylaia Thessaloniki, 570 01, Greece

  • GSK Investigational Site

    Rio Patras, 26504, Greece

  • GSK Investigational Site

    Thessaloniki, 55236, Greece

  • GSK Investigational Site

    Thessaloniki, 57010, Greece

  • GSK Investigational Site

    Ancona, 60126, Italy

  • GSK Investigational Site

    Avellino, 83100, Italy

  • GSK Investigational Site

    Florence, 50134, Italy

  • GSK Investigational Site

    Milan, 20132, Italy

  • GSK Investigational Site

    Milan, 20133, Italy

  • GSK Investigational Site

    Monza, 20900, Italy

  • GSK Investigational Site

    Napoli, 80131, Italy

  • GSK Investigational Site

    Orbassano to, 10043, Italy

  • GSK Investigational Site

    Perugia, 06156, Italy

  • GSK Investigational Site

    Siena, 53100, Italy

  • GSK Investigational Site

    Kyoto, 612-8555, Japan

  • GSK Investigational Site

    Miyagi, 981-1293, Japan

  • GSK Investigational Site

    Osaka, 591-8555, Japan

  • GSK Investigational Site

    Yamaguchi, 755-0241, Japan

  • GSK Investigational Site

    Guadalajara, 44280, Mexico

  • GSK Investigational Site

    Mexico City, 03100, Mexico

  • GSK Investigational Site

    Mexico City, 03810, Mexico

  • GSK Investigational Site

    Mexico City, 06700, Mexico

  • GSK Investigational Site

    Mexico City, CP 14080, Mexico

  • GSK Investigational Site

    Monterrey, 64460, Mexico

  • GSK Investigational Site

    Puebla Puebla, 72560, Mexico

  • GSK Investigational Site

    Amersfoort, 3813 TZ, Netherlands

  • GSK Investigational Site

    Enschede, 7512 KZ, Netherlands

  • GSK Investigational Site

    Groningen, 9713 GZ, Netherlands

  • GSK Investigational Site

    Harderwijk, 3844 DG, Netherlands

  • GSK Investigational Site

    Nijmegen, 6525 GA, Netherlands

  • GSK Investigational Site

    Utrecht, 3543 AZ, Netherlands

  • GSK Investigational Site

    Zwolle, 8025 AB, Netherlands

  • GSK Investigational Site

    Bydgoszcz, 85-796, Poland

  • GSK Investigational Site

    Gdynia, 81-519, Poland

  • GSK Investigational Site

    Lodz, 90-338, Poland

  • GSK Investigational Site

    Olsztyn, 10-357, Poland

  • GSK Investigational Site

    Piła, 64-920, Poland

  • GSK Investigational Site

    Poznan, 60-693, Poland

  • GSK Investigational Site

    Bucharest, 013812, Romania

  • GSK Investigational Site

    Craiova, 200347, Romania

  • GSK Investigational Site

    Craiova Dolj, 200385, Romania

  • GSK Investigational Site

    Otopeni, 075100, Romania

  • GSK Investigational Site

    Timișoara, 300239, Romania

  • GSK Investigational Site

    Chelyabinsk, 454048, Russia

  • GSK Investigational Site

    Moscow Region, 143423, Russia

  • GSK Investigational Site

    Pushkin, 196603, Russia

  • GSK Investigational Site

    Saint Petersburg, 197022, Russia

  • GSK Investigational Site

    Cheongju Chungcheongbuk-do, 28644, South Korea

  • GSK Investigational Site

    Daegu, 42601, South Korea

  • GSK Investigational Site

    Gyeonggi-do, 10408, South Korea

  • GSK Investigational Site

    Pusan, 49241, South Korea

  • GSK Investigational Site

    Seongnam-si Gyeonggi-do, 13620, South Korea

  • GSK Investigational Site

    Seoul, 03722, South Korea

  • GSK Investigational Site

    Seoul, 05505, South Korea

  • GSK Investigational Site

    Seoul, 06351, South Korea

  • GSK Investigational Site

    Seoul, 08308, South Korea

  • GSK Investigational Site

    Suwon Kyunggi-do, 443-721, South Korea

  • GSK Investigational Site

    A Coruña, 15006, Spain

  • GSK Investigational Site

    Badalona, 08916, Spain

  • GSK Investigational Site

    Barcelona, 08035, Spain

  • GSK Investigational Site

    Barcelona, 08036, Spain

  • GSK Investigational Site

    Burgos, 09006, Spain

  • GSK Investigational Site

    Córdoba, 140044, Spain

  • GSK Investigational Site

    Las Palmas de Gran Canar, 35016, Spain

  • GSK Investigational Site

    Madrid, 28007, Spain

  • GSK Investigational Site

    Madrid, 28034, Spain

  • GSK Investigational Site

    Madrid, 28041, Spain

  • GSK Investigational Site

    Madrid, 28046, Spain

  • GSK Investigational Site

    Madrid, 28050, Spain

  • GSK Investigational Site

    Madrid, 28222, Spain

  • GSK Investigational Site

    Málaga, 29010, Spain

  • GSK Investigational Site

    Valencia, 46026, Spain

  • GSK Investigational Site

    Gävle, SE-801 87, Sweden

  • GSK Investigational Site

    Stockholm, 171 64, Sweden

  • GSK Investigational Site

    Uppsala, SE-751 85, Sweden

  • GSK Investigational Site

    Taipei, 11217, Taiwan

  • GSK Investigational Site

    Dusit, 10300, Thailand

  • GSK Investigational Site

    Kho Hong Hat Yai, 90110, Thailand

  • GSK Investigational Site

    Khon Kaen, 40002, Thailand

  • GSK Investigational Site

    Pathum Thani, 12120, Thailand

  • GSK Investigational Site

    Adana, 1120, Turkey (Türkiye)

  • GSK Investigational Site

    Antalya, 07020, Turkey (Türkiye)

  • GSK Investigational Site

    Izmir, 35600, Turkey (Türkiye)

  • GSK Investigational Site

    Cardiff, CF14 2TL, United Kingdom

  • GSK Investigational Site

    Edinburgh, EH4 2XU, United Kingdom

  • GSK Investigational Site

    London, SE1 9RT, United Kingdom

  • GSK Investigational Site

    London, W1G 6AD, United Kingdom

  • GSK Investigational Site

    Manchester, M20 4BX, United Kingdom

Conditions

Explore the condition pages connected to this study.